Search results for "endocrine"

showing 10 items of 2114 documents

Abstract 2141: Stromal SPARC deficiency skews prostate cancer toward neuroendocrine differentiation

2018

Abstract Tumor progression is a multifaceted process in which, complex interactions between tumor and different types of stromal cells and extracellular matrix components, actively contribute to its phenotypic heterogeneity. Among extracellular matrix proteins, secreted protein acidic and rich in cysteine (SPARC) has been deeply studied since conflicting reports have described its expression to be either increased or decreased in different cancer settings, also depending on whether it is produced by the neoplasm or by the neighboring stroma. Nevertheless, the different contribution of tumor- or stromal-derived SPARC in prostate tumor microenvironment has not been addressed at least for tumo…

Cancer ResearchTumor microenvironmentStromal cellCancerBiologymedicine.diseaseNeuroendocrine differentiationProstate cancerOncologyTumor progressionmedicineCancer researchAdenocarcinomaTrampCancer Research
researchProduct

Tenascin in denervated human muscle

1996

Tenascin is a large oligomeric glycoprotein of the extracellular matrix. Its location is limited in innervated muscle tissues. We investigated immunohistologically, using two monoclonal antibodies (mab) against Tenascin, biopsied denervated human muscle of children and adults. Tenascin was present in the interstitial space among denervated muscle fibres. Accumulation of Tenascin in denervated adult muscle tissue was frequent, accumulation in denervated muscle tissue of children was sparse and weak. The two antibodies reacted correspondingly. Tenascin was not only found in the vicinity of atrophic muscle fibres, but also close to normally sized fibres, suggesting an early stage of denervatio…

chemistry.chemical_classificationMuscle tissueDenervationendocrine systemPathologymedicine.medical_specialtyanimal structuresbiologymedicine.drug_classTenascinmusculoskeletal systemMonoclonal antibodyExtracellular matrixmedicine.anatomical_structureNeurologychemistryInterstitial spaceembryonic structuresmedicinebiology.proteinImmunohistochemistryNeurology (clinical)GlycoproteinJournal of the Neurological Sciences
researchProduct

Pharmacotherapy for gestational diabetes

2018

Introduction: Gestational diabetes mellitus (GDM) represents impaired carbohydrate metabolism during pregnancy and is characterized by progressive insulin resistance and compensatory hyperinsulinaemia. If inadequately treated, it may lead to fetal macrosomia and other adverse outcomes. Areas covered: In this review, the authors summarize the current evidence from studies on the use of insulin and other agents for the treatment of women with GDM. Expert opinion: Lifestyle management is of paramount importance for the treatment of GDM. In pharmacotherapy, insulin remains the long-established mainstay of treatment. NPH (Neutral Protamine Hagedorn) and soluble human insulin have long been estab…

medicine.medical_specialtyinsulinlifestyleendocrine system diseasesmedicine.medical_treatment030209 endocrinology & metabolismCarbohydrate metabolism03 medical and health sciences0302 clinical medicineInsulin resistancePharmacotherapyPregnancyInternal medicineHumansMedicineHypoglycemic AgentsPharmacology (medical)030212 general & internal medicineDipeptidyl-Peptidase IV InhibitorsPharmacologyDipeptidyl-Peptidase IV InhibitorsPregnancytherapybusiness.industryInsulinnutritional and metabolic diseasesGeneral Medicinemedicine.diseaseincretinPregnancy ComplicationPregnancy ComplicationsGestational diabetesDiabetes GestationalEndocrinologyGestational diabeteDipeptidyl-Peptidase IV InhibitorFemalebusiness
researchProduct

Molecular Basis for Endocrine Disruption by Pesticides Targeting Aromatase and Estrogen Receptor

2020

The intensive use of pesticides has led to their increasing presence in water, soil, and agricultural products. Mounting evidence indicates that some pesticides may be endocrine disrupting chemicals (EDCs), being therefore harmful for the human health and the environment. In this study, three pesticides, glyphosate, thiacloprid, and imidacloprid, were tested for their ability to interfere with estrogen biosynthesis and/or signaling, to evaluate their potential action as EDCs. Among the tested compounds, only glyphosate inhibited aromatase activity (up to 30%) via a non-competitive inhibition or a mixed inhibition mechanism depending on the concentration applied. Then, the ability of the thr…

aromatasemedicine.drug_classHealth Toxicology and Mutagenesislcsh:MedicineEstrogen receptorMixed inhibitionEndocrine Disruptors010501 environmental sciencesPharmacology01 natural sciencesArticle03 medical and health scienceschemistry.chemical_compoundImidaclopridReceptorsmedicineHumansAromataseestrogenic activity030304 developmental biology0105 earth and related environmental sciences0303 health sciencesAromatase inhibitorendocrine disrupting chemicalbiologyAromatase Inhibitorslcsh:RPublic Health Environmental and Occupational HealthEstrogenspesticidesPesticideThiaclopridEstrogenmolecular dynamicsReceptors EstrogenchemistryEstrogenMELN allosteric inhibitionbiology.proteingene reporter assayAromatase; Endocrine disrupting chemical; Estrogen receptor; Estrogenic activity; Gene reporter assay; MELN allosteric inhibition; Molecular dynamics; Neonicotinoids; Pesticides; Aromatase; Aromatase Inhibitors; Estrogens; Humans; Receptors Estrogen; Endocrine Disruptors; Pesticidesneonicotinoidsestrogen receptorInternational Journal of Environmental Research and Public Health
researchProduct

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.

2014

BRAF-V600E expression is identified in hematopoietic progenitor and precursor myeloid dendritic cells in patients with high-risk LCH, and enforced expression of BRAF-V600E in CD11c+ cells recapitulates a high-risk LCH-like phenotype in mice.

MalePathologyendocrine system diseasesCellular differentiationCD34Antigens CD34Mice0302 clinical medicineLangerhans cell histiocytosisBone MarrowRisk FactorsImmunology and Allergyskin and connective tissue diseasesChild0303 health sciencesCell Differentiation3. Good healthHistiocytosismedicine.anatomical_structurePhenotypeTreatment Outcome030220 oncology & carcinogenesisChild PreschoolAntigens Surface2723 Immunology and AllergyFemaleProto-Oncogene Proteins B-rafmedicine.medical_specialtyImmunologyCD11c610 Medicine & healthBiologyArticle03 medical and health sciencesGermline mutationmedicineAnimalsHumansCell LineageGenetic Predisposition to DiseaseLectins C-TypeProgenitor cellneoplasms030304 developmental biology2403 ImmunologyHistocompatibility Antigens Class II302InfantCorrectionDendritic Cellsmedicine.diseaseHematopoietic Stem Cellsdigestive system diseasesCD11c Antigenenzymes and coenzymes (carbohydrates)Histiocytosis Langerhans-CellMannose-Binding Lectins10032 Clinic for Oncology and HematologyMutationBone marrowThe Journal of experimental medicine
researchProduct

Properties of Resveratrol:In VitroandIn VivoStudies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans

2015

Plants containing resveratrol have been used effectively in traditional medicine for over 2000 years. It can be found in some plants, fruits, and derivatives, such as red wine. Therefore, it can be administered by either consuming these natural products or intaking nutraceutical pills. Resveratrol exhibits a wide range of beneficial properties, and this may be due to its molecular structure, which endow resveratrol with the ability to bind to many biomolecules. Among these properties its activity as an anticancer agent, a platelet antiaggregation agent, and an antioxidant, as well as its antiaging, antifrailty, anti-inflammatory, antiallergenic, and so forth activities, is worth highlightin…

AgingAntioxidantendocrine system diseasesmedicine.medical_treatmentAnti-Inflammatory AgentsBiological AvailabilityAntineoplastic AgentsApoptosisReview ArticleResveratrolPharmacologyBiologyBiochemistryAntioxidantschemistry.chemical_compoundNutraceuticalPharmacokineticsIn vivoStilbenesmedicineAnimalsHumansSirtuinslcsh:QH573-671lcsh:Cytologyorganic chemicalsfood and beveragesCell BiologyGeneral MedicineMetabolismIn vitroBioavailabilitychemistryBiochemistryResveratrolModels AnimalOxidoreductasesOxidative Medicine and Cellular Longevity
researchProduct

Dietary exposure in utero and during lactation to a mixture of genistein and an anti-androgen fungicide in a rat mammary carcinogenesis model

2015

Endocrine disruptors may play substantial roles in the high incidence of breast cancer. We previously described how early exposure to the mixture of phytoestrogen genistein (G) and the anti-androgen vinclozolin (V) affects peripubertal mammary development. This study evaluates the carcinogenic potential of exposure to V alone or associated with G from conception until weaning in Wistar rats. Dams were exposed to V, G or GV during pregnancy/lactation. At PND50 offspring were treated with DMBA[7,12-dimethylbenz(a)anthracene]. V or GV maternal exposure decreased number of DMBA-induced mammary tumors in the offspring, without significant modifications in tumor incidence, multiplicity and latenc…

[ SDV.AEN ] Life Sciences [q-bio]/Food and NutritionGenisteinDMBAEndocrine DisruptorsToxicologymedicine.disease_causechemistry.chemical_compound0302 clinical medicinePregnancyRisk FactorsLactationVinclozolinOxazoles0303 health sciencesAge Factorsendocrine disruptionGenisteinTumor Burden3. Good health[ SDV.BDLR ] Life Sciences [q-bio]/Reproductive Biologymedicine.anatomical_structuregestational and lactational exposureReceptors EstrogenMaternal ExposureIn utero030220 oncology & carcinogenesisphytoestrogenFemaleReceptors ProgesteroneCarcinoma in Situmedicine.medical_specialtyendocrine systemanti-androgenOffspring910-Dimethyl-12-benzanthraceneBreast NeoplasmsGestational AgeBiologyRisk Assessment03 medical and health sciencesMammary Glands AnimalPrenatal Educationmammary gland carcinogenesisInternal medicinemedicineAnimalsEndocrine systemRats WistarCell Proliferation030304 developmental biologyAndrogen AntagonistsEpithelial Cells[SDV.BDLR]Life Sciences [q-bio]/Reproductive BiologyDietFungicides IndustrialDisease Models AnimalEndocrinologychemistryCarcinogenesis[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Role of exercise-induced hepatokines in metabolic disorders.

2019

International audience; The health-promoting effects of physical activity to prevent and treat metabolic disorders are numerous. However, the underlying molecular mechanisms are not yet completely deciphered. In recent years, studies have referred to the liver as an endocrine organ, since it releases specific proteins called hepatokines. Some of these hepatokines are involved in whole body metabolic homeostasis and are theorized to participate in the development of metabolic disease. In this regard, the present review describes the role of Fibroblast Growth Factor 21, Fetuin-A, Angiopoietin-like protein 4, and Follistatin in metabolic disease and their production in response to acute exerci…

medicine.medical_specialtyFGF21PhysiologyEndocrinology Diabetes and MetabolismPhysical activity030209 endocrinology & metabolism03 medical and health sciences0302 clinical medicineMetabolic DiseasesRegular exerciseNon-alcoholic Fatty Liver DiseasePhysiology (medical)Internal medicineEndocrine systemMedicineAnimalsHumansObesityMetabolic diseaseBeneficial effectsExercise030304 developmental biology0303 health sciencesbiologybusiness.industry[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism3. Good healthEndocrinologyDiabetes Mellitus Type 2Liverbiology.proteinCytokinesInsulin ResistanceWhole bodybusinessFollistatinAmerican journal of physiology. Endocrinology and metabolism
researchProduct

Metformin and contrast-induced acte kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevati…

2016

IF 4.638; International audience; AIM : To analyze the association between chronic metformin treatment and the development of contrast-induced acute kidney injury (CI-AKI) after primary percutaneous coronary intervention (PCI) for ST segment elevation myocardial infarction (STEMI).METHODS: Patients with type 2 diabetes mellitus (T2DM) treated with PCI 27μmol/l (0.3mg/dl) or >50% over baseline after PCI. Since PCI was urgent, metformin could not be withheld prior to PCI but was usually stopped after PCI.RESULTS:Among the 372 patients included, 147 (40%) were using metformin, which had older diabetes, but had risk factors similar to patients without metformin. Baseline eGFR was better in pati…

Malemedicine.medical_specialtyendocrine system diseasesMedication Therapy Managementmedicine.medical_treatmentStatistics as TopicContrast Media030204 cardiovascular system & hematologyCoronary AngiographyRisk Assessment03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsST segment030212 general & internal medicineMyocardial infarctioncardiovascular diseasesAgedbusiness.industryPrimary percutaneous coronary interventionAcute kidney injuryPercutaneous coronary interventionnutritional and metabolic diseasesMiddle Aged[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[ SDV.MHEP.EM ] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmedicine.diseaseST segment elevation segment myocardial infarctionMetformin3. Good healthMetforminAcute kidney injuryDiabetes Mellitus Type 2CreatinineConventional PCICardiologyST Elevation Myocardial InfarctionFemaleFranceCardiology and Cardiovascular MedicinebusinessKidney diseasemedicine.drug
researchProduct

Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study

2016

Background Luminal A breast cancers respond well to anti-hormonal therapy (HT), are associated with a generally favorable prognosis and constitute the majority of breast cancer subtypes. HT is the mainstay of treatment of these patients, accompanied by an acceptable profile of side effects, whereas the added benefit of chemotherapy (CHT), including anthracycline and taxane-based programs, is less clear-cut and has undergone a process of critical revision. Methods In the framework of the BRENDA collective, we analyzed the benefits of CHT compared to HT in 4570 luminal A patients (pts) with primary diagnosis between 2001 and 2008. The results were adjusted by nodal status, age, tumor size and…

Oncologymedicine.medical_treatmentCancer Treatmentlcsh:MedicineBiochemistry0302 clinical medicineBreast TumorsMedicine and Health Sciences030212 general & internal medicinelcsh:ScienceAged 80 and overMultidisciplinaryPharmaceuticsHormonal TherapyEndocrine TherapyMiddle AgedSurvival RateOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleAnatomyResearch Articlemedicine.drugClinical OncologyAdultmedicine.medical_specialtyAnthracyclineBreast NeoplasmsDisease-Free SurvivalLymphatic System03 medical and health sciencesBreast cancerDrug TherapyDiagnostic MedicineInternal medicineBreast CancerCancer Detection and DiagnosismedicineChemotherapyHumansddc:610Survival rateGrading (tumors)AgedRetrospective StudiesChemotherapyTaxanebusiness.industrylcsh:RCancers and NeoplasmsBiology and Life SciencesRetrospective cohort studymedicine.diseaseHormonesSurgerylcsh:QLymph NodesClinical MedicinebusinessTamoxifenPLOS ONE
researchProduct